Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | JANX | Common Stock | Conversion of derivative security | +1.14M | +592.59% | 1.33M | Jun 15, 2021 | Direct | F1, F2 | ||
transaction | JANX | Common Stock | Conversion of derivative security | +2.38M | +179% | 3.71M | Jun 15, 2021 | Direct | F1, F2 | ||
transaction | JANX | Common Stock | Conversion of derivative security | +674K | +18.16% | 4.39M | Jun 15, 2021 | Direct | F1, F2 | ||
transaction | JANX | Common Stock | Conversion of derivative security | +2.7M | 2.7M | Jun 15, 2021 | See footnote | F1, F3 | |||
transaction | JANX | Common Stock | Conversion of derivative security | +1.15M | +42.76% | 3.85M | Jun 15, 2021 | See footnote | F1, F3 | ||
transaction | JANX | Common Stock | Purchase | $10.7M | +629K | +16.35% | $17.00 | 4.48M | Jun 15, 2021 | See footnote | F3, F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | JANX | Series Seed Convertible Preferred Stock | Conversion of derivative security | -889K | -100% | 0 | Jun 15, 2021 | Common Stock | 1.14M | Direct | F1, F2 | |||
transaction | JANX | Series Seed 2 Convertible Preferred Stock | Conversion of derivative security | -1.86M | -100% | 0 | Jun 15, 2021 | Common Stock | 2.38M | Direct | F1, F2 | |||
transaction | JANX | Series A Convertible Preferred Stock | Conversion of derivative security | -526K | -100% | 0 | Jun 15, 2021 | Common Stock | 674K | Direct | F1, F2 | |||
transaction | JANX | Series A Convertible Preferred Stock | Conversion of derivative security | -2.11M | -100% | 0 | Jun 15, 2021 | Common Stock | 2.7M | See footnote | F1, F3 | |||
transaction | JANX | Series B Convertible Preferred Stock | Conversion of derivative security | -900K | -100% | 0 | Jun 15, 2021 | Common Stock | 1.15M | See footnote | F1, F3 |
Id | Content |
---|---|
F1 | Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. |
F2 | The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kevin Kinsella, Richard Levandov, Braden Bohrmann and Jay Lichter, Ph.D. are managing members of Avalon XI GP. Mr. Kinsella, Mr. Levandov, Mr. Bohrmann and Dr. Lichter share voting and investment power with respect to the shares held by Avalon Ventures. Each of such individuals disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of each such individual's actual pecuniary interest therein, if any. |
F3 | The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter and Tighe Reardon share voting and investment power with respect to the shares held by ABV SPV. Each of such individuals disclaims beneficial ownership of all shares held by ABV SPV except to the extent of each such individual's actual pecuniary interest therein, if any. |
F4 | The shares were purchased in the Issuer's initial public offering. |